


WHAT IS CLAIMED IS:

1. A composition for promoting wound healing, comprising a pharmaceutically effective amount of a compound in combination with a pharmaceutically acceptable carrier, said compound being a member of a group having a formula:



wherein:


R_1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy;

R_2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, and

R_3 is a member of the group consisting of hydrogen and lower alkenoxy; and n is either 1 or 2; and pharmaceutically acceptable salts thereof.

2. A composition according to claim 1, wherein said compound is Halofuginone and pharmaceutically acceptable salts thereof.

3. A method of manufacturing a medicament for promoting wound healing, comprising the step of placing a pharmaceutically effective amount of a compound in a pharmaceutically acceptable carrier, said compound being a member of a group having a formula:



wherein:


R_1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy;

R_2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, and

R_3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; and n is either 1 or 2;

and pharmaceutically acceptable salts thereof.

4. A method of manufacturing a medicament for administration before a performance of a surgical procedure, for promotion of wound healing, the method comprising the step of placing a pharmaceutically effective amount of a compound in a pharmaceutically acceptable carrier, said compound being a member of a group having a formula:



wherein:


R_1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy;

R_2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, and

R_3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; and n is either 1 or 2;

and pharmaceutically acceptable salts thereof.

5. A composition for treatment, substantially before a performance of a surgical procedure, for promotion of wound healing, the composition comprising a pharmaceutically effective amount of a compound having a formula:



wherein:


R_1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy;

R_2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy, and

R_3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; and n is either 1 or 2;

and pharmaceutically acceptable salts thereof.

6. A composition for treating a stricture in a subject, comprising a pharmaceutically effective amount of a compound having a formula:



wherein:

R_1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy;

R_2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy, and

R_3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; and n is either 1 or 2;

and pharmaceutically acceptable salts thereof.

7. The composition of claim 6, wherein the stricture is an urethral stricture.


8. The composition of claim 7, wherein the urethral stricture arises after a surgical procedure is performed in the subject.

9. The composition of claim 8, wherein said surgical procedure is catheterization of the urethra of the subject.

10. The composition of claim 7, wherein the urethral stricture arises after an infection of the urethra of the subject.

11. The composition of claim 7, wherein said compound is administered to the subject through transurethral administration.

- ✓
12. A method for treating a stricture in a subject, comprising the step of administering to the subject a pharmaceutically effective amount of a compound having a formula:



wherein:

R_1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy;

R_2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy, and

R_3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; and n is either 1 or 2;

and pharmaceutically acceptable salts thereof.

13. The method of claim 12, wherein the stricture is an urethral stricture.


14. The method of claim 13, wherein the urethral stricture arises after a surgical procedure is performed in the subject.

15. The method of claim 14, wherein said surgical procedure is catheterization of the urethra of the subject.

16. The method of claim 13, wherein the urethral stricture arises after an infection of the urethra of the subject.

17. The method of claim 13, wherein said compound is administered to the subject through transurethral administration.

- ✓
18. A composition for preventing cicatrix formation in a subject while maintaining a strength of a wound, comprising a pharmaceutically effective amount of a compound having a formula:



wherein:

R_1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy;

R_2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy, and

R_3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; and n is either 1 or 2;

and pharmaceutically acceptable salts thereof;

wherein said compound is administered to the subject, such that the strength of the wound of the subject is not decreased.